# Massimiliano Dendi

> Massimiliano Dendi is a Series A investor at One Factory backing Biotechnology and Software. See 8 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [One Factory](https://shizune.co/investors/profile/one-factory)
- Location: Milan, Italy
- Total investments: 8
- Last investment: Feb 2023
- Lead investor: 13%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/massimiliano-dendi-5289263?miniProfileUrn=urn%3Ali%3Afs_miniProfile%3AACoAAACrqXABMAMy-W3I75jlFH6n1tfzzqkbmY4&lipi=urn%3Ali%3Apage%3Ad_flagship3_search_srp_all%3Bgy0Av%2FCdRXeb8qtpEc1e6Q%3D%3D
- X (Twitter): https://twitter.com/massydandy
- Website: https://x.com/massydandy
- Facebook: https://www.facebook.com/massimiliano.dendi

Massimiliano Dendi is a Series A investor at One Factory in Milan focused on Biotechnology and Software. Massimiliano Dendi is the Founder and CEO of One Factory. He previously worked at Net4Capital as a Co-Founder. Massimiliano Dendi attended the University of Pisa.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 38% |
| Software | 2 | 25% |
| Aerospace | 2 | 25% |
| Health Care | 2 | 25% |
| Drones | 1 | 13% |

22 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 6 | 75% |
| Series B | 1 | 13% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Olatec Therapeutics | Olatec is a privately held biopharmaceutical company developing a platform of safe, oral NLRP3 antagonist therapeutics, to treat and prevent a broad spectrum of acute and chronic inflammatory diseases that are known to be mediated by Interleukin-1 (IL-1), including: arthritis, heart failure, asthma, Parkinson's and Alzheimer’s disease, spinalcord injury, multiple sclerosis, type-2 diabetes, melanoma, pancreatic and breast cancers, among others.By selectively targeting NLRP3, the body’s first line response in the innate immune system, Olatec’s lead compound, dapansutrile (lab code: OLT1177®) inhibits the production of pro-inflammatory cytokines IL 1B and IL 18Olatec’s drug development team, working together over 10 years, is comprised of experienced management and international thought leaders that have unparalleled expertise in inflammation and immunology and have been involved in the discovery and development of first-line inflammation treatments in the market today. The Company conducts operations in the United States and Europe and maintains offices in New York and the Netherlands. | $40M | Series A | Feb 23, 2023 |  |
| VitroLabs | VitroLabs is a startup working on the cutting edge of 3D tissue engineering using stem cell-based technologies. The company develops a fully scalable tissue engineering platform combining the latest breakthroughs in stem cell research and biomaterials. It manufactures real leather without the need to raise and slaughter animals using breakthroughsin stem cell research and tissue engineering.VitroLabs was founded on 2016 and is based in San Jose, California. | $47.4M | Series A | May 04, 2022 |  |
| HelixNano | Helix Nanotechnologies uses artificial intelligence to help cure genetic diseases. HelixNano is a Y Combinator and venture backed biotech startup. At HelixNano, we have spent the last two years developing cancer vaccines. Now we are adapting our synthetic biology arsenal to take on COVID-19. We’re moving fast but thinking long-term. We’re alreadytesting COVID-19 vaccine candidates designed to be precise and safe. Our next goal is to create a vaccine that protects everyone not only from this virus, but all future coronaviruses. | $45M | Series A | Mar 22, 2022 |  |
| Olatec Therapeutics | Olatec is a privately held biopharmaceutical company developing a platform of safe, oral NLRP3 antagonist therapeutics, to treat and prevent a broad spectrum of acute and chronic inflammatory diseases that are known to be mediated by Interleukin-1 (IL-1), including: arthritis, heart failure, asthma, Parkinson's and Alzheimer’s disease, spinalcord injury, multiple sclerosis, type-2 diabetes, melanoma, pancreatic and breast cancers, among others.By selectively targeting NLRP3, the body’s first line response in the innate immune system, Olatec’s lead compound, dapansutrile (lab code: OLT1177®) inhibits the production of pro-inflammatory cytokines IL 1B and IL 18Olatec’s drug development team, working together over 10 years, is comprised of experienced management and international thought leaders that have unparalleled expertise in inflammation and immunology and have been involved in the discovery and development of first-line inflammation treatments in the market today. The Company conducts operations in the United States and Europe and maintains offices in New York and the Netherlands. |  | Series A | Mar 16, 2022 |  |
| Skydweller | Skydweller is a US-Spanish aerospace company developing solar powered aircraft solutions capable of achieving perpetual flight with the highest—and most meaningful—payload capacity. Utilizing technology based upon the longest continuous solar powered flight program in history, our fast-growing startup is developing a new class of unmanned aircraft,providing the persistence of geosynchronous satellites with the powerful sensing capabilities and range of a large, airborne platform. | $40M | Series A | Sep 09, 2021 |  |
| Elroy Air | Elroy Air is a logistics company that specializes in the fields of logistics, robotics, and air transportation. Its air cargo system features rotor-based vertical takeoff and landing (VTOL) and transitions to wing-based cruise flight for long-range. It was founded in 2016 and headquartered in San Francisco, California. | $40M | Series A | Aug 04, 2021 |  |
| Sonatus | Sonatus delivers technology and solutions that accelerate vehicle software innovation. Their platforms and products serve as key building blocks that allow automotive companies and their ecosystem to deliver continuous improvements in costs, capabilities, reliability, and user experience over the vehicle lifespan, realizing the promise ofsoftware-defined vehicles. | $35M | Series A | Jul 21, 2021 |  |
| MemVerge | MemVerge is delivering the world’s first Memory-Converged Infrastructure (MCI) system, built with proprietary Distributed Memory Objects (DMO) technology. DMO technology provides a logical convergence layer that harnesses Intel’s new Optane DC persistent memory to let data-centric workloads run flawlessly at memory speed. | $19M | Series B | May 12, 2020 |  |

8 of 8 investments shown.

## Co-investors
- [Cliffs](https://shizune.co/investors/profile/cliffs) — VC Fund, 3 deals together
- [Advection Growth Capital](https://shizune.co/investors/profile/advection-growth-capital) — VC Fund, 2 deals together
- [Intel Capital](https://shizune.co/investors/profile/intel-capital) — VC Fund, 2 deals together
- [Marlinspike Capital](https://shizune.co/investors/profile/marlinspike) — VC Fund, 2 deals together
- [Sanders Morris Harris](https://shizune.co/investors/profile/sanders-morris-harris) — VC Fund, 2 deals together
- [Yes VC](https://shizune.co/investors/profile/yes-vc) — VC Fund, 2 deals together

## About One Factory

VC Fund



1 contacts available at One Factory.

| Name | Title | Profile |
| --- | --- | --- |
| Massimiliano Dendi | CEO & Founder | https://shizune.co/investors/profile/massimiliano-dendi |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Massimiliano Dendi invest in?

Massimiliano Dendi invests primarily in Biotechnology, Software and Aerospace startups, most often at Series A and Series B stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Massimiliano Dendi last invest?

The most recent investment recorded for Massimiliano Dendi closed in Feb 2023. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co